Podcasts about GBM

#Podcast #MéxicoVsGoogle #TrumpMobile #aibipocketEn este episodio te contamos todo sobre la demanda del gobierno mexicano contra Google, y el caso en Puebla donde una persona podría ir a la cárcel por insultos en redes. Además, Trump anuncia su propio celular: Trump Mobile. También conocimos el Aibi Pocket, un gadget estilo Tamagotchi pero potenciado con inteligencia artificial, y unos lentes que integran pantalla. Cerramos con entrevista a GBM, el supuesto “WhatsApp de Twitter” y nuestra opinión sobre la película de F1 que ya vimos.

Bobby Dutton | Founder ,GBM 6  Bobby Dutton, an entrepreneur and philanthropist who has pioneered innovative event design and operational strategies in the live events industry. His concept of "pilot thinking" offers a unique approach to achieving happiness and efficiency.Bobby, being a licensed commercial pilot, brings a fresh perspective that could intrigue your audience. He can provide actionable insights on leadership and success by drawing parallels from both the aviation and event management sectors.His work has impacted 2.5M+ people across 47 states and counting. He love helping organizations, colleges, and businesses create experiences that energize, inspire, and drive results.He  also help teams and leaders work smarter, move faster, and thrive under pressure. Whether it's time management, team efficiency, or building a culture of creativity, He bring insights from event production, engineering, music, and even aviation.  

Short biographies of important people from church history. This series highlights key aspects of their lives, what they are most known for and what we can learn from them. #HistoricalCharacters #churchhistory #IndianChristians #VankateswaraThyaharaj #Rajan #AmyWilsonCarmichael #DohnavurFellowship #illness #depression #leprosy #Hansensdisease #Chennai #Madras #clinic #poorpeople #NewYork #TamilNadu #Brahmin #kidnapped #faithfultoJesus #Veera A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #Forget #Thankfulness #countblessings #providence #attitudeofgratitude #Psalm103v1-2 #Psalm121v7-8 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

This week on Gabe's Big Move Gabe answer the question, how has COVID and bingewatching changed the way contestants play #Survivor? Plus the first guest in the history of GBM joins the show! All that and more tonight on Gabe's Big Move brought to you by the Reality Aftershow 

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. David Akhavan, a physician-scientist pioneering cell therapy research for brain cancer. Dr. Akhavan discusses the revolutionary potential of chimeric antigen receptor (CAR) T-cell therapy in treating cancers like glioblastoma, the complexities involved and the innovative approaches his team is employing, such as smarter engineered T-cells and nanoparticles. Highlighting the collaboration within KU Cancer Center, Dr. Akhavan also shares personal insights into his motivation and the future of cancer treatment. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about cell therapy at KU Cancer Center Learn more about brain cancer Read more about Dr. Akhavan's work on the KU Cancer Center blog, “Exploring Immunotherapy Treatments to Treat Brain Cancer” Learn about Head for the Cure Read how physician-scientists at KU Cancer Center bridge the gap between the laboratory and the clinic  

Short biographies of important people from church history. This series highlights key aspects of their lives, what they are most known for and what we can learn from them. #HistoricalCharacters #churchhistory #RobertMurrayMCheyne #Scotland #Edinburgh #hymn #IwasastrangertograceandtoGod #preacheroftheGospel #Dundee #beatutyofChrist #pastoralministry #StPetersChurch #letterwriting #churchlibrary #Typhus #JehovahTsidkenu A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #TrustGod #anxiety #fear #rememberGod #Godslove #Godincontrol #Godscare #peaceofGod #Psalm27v3 #John16v33 #Philippians4v7 #2Timothy1v7 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

The following article of the Finance & Fintech industry is: “How the ‘Sequence of Returns' Can Derail Retirement Plans” by Juan Carlos Herrera, Chief of Advisory and Investment Solutions, GBM.

Researchers at Brown University have developed a combination treatment that significantly increases survival in mice with glioblastoma (GBM), a highly aggressive and treatment-resistant brain cancer. The approach uses a new class of drugs called imipridones along with radiation therapy and standard chemotherapy. This triple therapy, known as IRT, was recently detailed in a study published in Oncotarget. Understanding Glioblastoma and the Need for Better Therapies Glioblastoma is the most common and aggressive malignant brain tumor in adults. It grows quickly and is difficult to treat, often leading to poor outcomes. Most patients survive less than 15 months after diagnosis, even when treated with surgery, radiation, and the chemotherapy drug temozolomide (TMZ). This treatment may slow the disease, but it does not typically stop it. Full blog - https://www.oncotarget.org/2025/06/04/experimental-triple-therapy-improves-survival-in-glioblastoma-mouse-model/ Paper DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, glioblastoma multiforme, IDH, ONC201, ONC206, MGMT, temozolomide, radiotherapy To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

En este episodio desde el North Capital Forum, me senté con Pedro de Garay, director general de GBM. Hablamos de cómo invierte el mexicano, qué errores comete al comenzar y qué tendencias están captando más lana hoy en día. También platicamos sobre inteligencia artificial, nearshoring, behavioral finance y cómo aprovechar mejor tu dinero a largo plazo. Una mirada honesta, directa y con datos reales sobre cómo se mueve el dinero en México.

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

Short biographies of important people from church history. This series highlights key aspects of their lives, what they are most known for and what we can learn from them. #HistoricalCharacters #churchhistory #AdoniramJudson #RhodeIsland #LondonMissionarySociety #AnnHassletine #India #Burma #Rangoon #Gospel #Burmese #torture #translation #Scriptures #EmilyChubbeck #pastor #preacher A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #Suffering #CSLewis #Godsmegaphone #Godincontrol #gracesufficient #thornintheflesh #service #2Corinthians12v7-10 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Short biographies of important people from church history. This series highlights key aspects of their lives, what they are most known for and what we can learn from them. #HistoricalCharacters #churchhistory #WilliamCarey #caste #Hindu #KrishnaPal #DrJohnThomas #salvation #Brahmins #Bengal #mantras #Bengali #persecuted #firstfruits #conversions #hardships #ambassadorfoChrist #faithfulwitness #Brahmanism A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #inthevalley #Overcomingfear #peace #anxiousthoughts #Godissovereign #trust #Psalm34v4 #Isaiah41v10 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

'DAVE ALLEN v DEONTAY WILDER...' - ADAM SMITH HONEST! / FURY v JOSHUA, PACQUIAO, GBM, FISHER, TAYLOR Learn more about your ad choices. Visit megaphone.fm/adchoices

Scientists have engineered small, targeted proteins that can penetrate brain cancer cells and prevent them from invading healthy tissue, offering a promising new approach to treating glioblastoma multiforme (GBM), one of the deadliest forms of brain cancer. This strategy was developed by researchers at the University of Nevada, Reno, and published recently in Oncotarget. The Challenge of Treating Glioblastoma Multiforme Glioblastoma is an aggressive and fast-growing brain tumor that infiltrates healthy brain tissue, making complete surgical removal nearly impossible. Standard treatments like chemotherapy and radiation can slow its growth but rarely prevent it from returning. One major reason for this invasiveness is a group of enzymes known as matrix metalloproteinases (MMPs), which break down surrounding tissue to allow cancer cells to spread. Among these, MMP-9 plays a particularly important role in driving tumor progression and resisting existing therapies. Attempts to block MMPs using small-molecule drugs have failed in clinical trials due to problems like poor selectivity and harmful side effects. Researchers have been searching for safer, more targeted methods to interfere with these enzymes and limit glioblastoma's spread. The Study: Engineered Proteins to Inhibit Tumor Invasion In the study called “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells,” researchers Elham Taheri and Maryam Raeeszadeh-Sarmazdeh investigated tissue inhibitors of metalloproteinases (TIMPs), which are natural blockers of MMPs, and their engineered modified versions made to work better. Specifically, the team studied TIMP-1, TIMP-3, along with two engineered molecules, mTC1 and mTC3, in laboratory cell models of GBM. Full blog - https://www.oncotarget.org/2025/05/21/engineered-proteins-show-promise-in-stopping-glioblastoma-invasion/ Paper DOI - https://doi.org/10.18632/oncotarget.28691 Correspondence to - Maryam Raeeszadeh-Sarmazdeh - maryamr@unr.edu Video short - https://www.youtube.com/watch?v=tdBlkOX50D8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28691 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, TIMP minimal variants, glioblastoma multiforme (GBM), brain cancer, MMP inhibitors To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

En este nuevo episodio de la sexta temporada de Análisis BIVA nos acompaña Miriam Acuña, Economista en Jefe de GBM, quien nos habla sobre la última decisión en materia de política monetaria por parte de Banxico, en qué consiste el nuevo acuerdo comercial entre EE.UU. y China, y la posible imposición de impuesto del 5% a las remesas. Conducido por Salvador Leal, Director de Comunicación de BIVA.

Overview of the prophecy of Nahum, one of the shortest of the minor prophets in the Old Testament. #MinorProphets #ProphecyofNahum #sermon #preaching #Nahum #Nineveh #Assyria #Samaria #divinedecree #longsuffering #kindnessofGod #ruthlessness #locusts #desertsand #compassionate #slowtoanger #judgmentday A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #Encouragement #Barnabas #Joseph #SaulofTarsus #rejection #discouragement #comfort #hope #Acts4v36-37 #Acts9v20-30 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Overview of the prophecy of Micah, the most well-known of the minor prophets in the Old Testament. #MinorProphets #ProphecyofMicah #sermon #preaching #promise #returnofexiles #mountainoftheLord #godliness #righteousness #lovemercy #actjustly #walkhumblywithyourGod #Godresiststheproud #selfdenial #Micah4v1-10 #Micah5v2 #Micah6v8 #Micah7v11 #Matthew5v7 From the Practical Preacher series: ‘Humility is key in Christian leadership. We need to have a servant attitude in our ministry' #PracticalPreacher #sacrificialservice #leadership #pride #humility #authority #gentleness #greatness #Matthew20v25-28 #John13v1-17 #1Thessalonians2v6-8 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Overview of the prophecy of Micah, one of the minor prophets in the Old Testament. #MinorProphets #ProphecyofMicah #Hezekiah #punishments #compassion #unfaithfulness #idolatry #Assyrians #lament #sorrow #sadness #2Kings18-19 #Micah1,5 Brief series on the miraculous gifts of the Spirit today in answer to a listener's question. #miraculousgiftsoftheSpirit #Healing #elders #anointingwithoil #prayeroffaith #sickness #thornintheflesh #sin #submissiontoGod #2Corinthians12v7-10 #James5v14-15 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Season 4 of Glioblastoma aka GBM kicks off Brain Tumor Awareness Month with a closer look at CeGaT, a genetic diagnostics company based in Tübingen, Germany. Founded in 2009 by Dr. Saskia Biskup and Dirk Biskup, CeGaT focuses on identifying rare diseases and tumor-specific mutations through advanced sequencing technologies. In this episode, we speak with Dr. Biskup and Florian Battke, Head of Research & Development, about what genetic sequencing is, how it's used in the context of brain tumors, and what they see as the next frontier for diagnosing and treating diseases like glioblastoma. We discuss how long-read sequencing may offer greater accuracy in identifying genetic changes and what that could mean for patients navigating difficult diagnoses. This episode explores the broader role that genomics can play in brain cancer research and the questions still left to answer as science continues to evolve. To learn more about the work CeGaT is doing, visit them online at https://cegat.com/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.

¿Crees que necesitas miles de pesos para empezar a invertir? En este episodio de Hablemos de Lana, un asesor de GBM nos explica cómo cualquier persona puede comenzar desde cero, sin ser experto ni millonario.

In episode 87 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Scott Kennedy, Director of Operations at Four Day Ray Brewing and Team Heroes athlete. Tune in for a peek inside the Indiana-based brewery and how the Team Heroes family supports each other, both on the bike and off. For more on Four Day Ray Brewing, visit fourdayray.com.

“Everyone's brain is extremely heterogenic, so it's different. You can put five of us in a room; we can all have the same diagnosis of a [glioblastoma multiforme], but all of ours can be different. They're highly aggressive biologically. It's a small area in a hard shell. So trying to get through the blood–brain barrier is different. There's a lot of areas of hypoxia in the brain. There's a lot of pressure there. The microbiology is very different—it's a cold environment versus a hot environment—and then the pathways are just different,” Lori Cappello, MSN, APN-C, CCRP, research advanced practice nurse at the John Theurer Cancer Center of Hackensack Meridian Health in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about brain malignancies and caring for patients with them. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 25, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to brain malignancies and their diagnosis and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 235: Self-Advocacy Skills for Patients Episode 166: Cognitive Behavioral Interventions Help Patients With a Spectrum of Cancer Symptoms ONS Voice articles: Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations Blocking Fatty Acid Storage May Induce Glioblastoma Apoptosis Brain Tumor Navigator Role Bridges the Intersection of Cancer and Neuroscience Researchers Tie More Cancers, Mortality to NF1 Disorders Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier McCain Announcement Sheds Light on Nurses' Role in Advance Care Planning ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Exercise Intervention: A Pilot Study to Assess the Feasibility and Impact on Cancer-Related Fatigue and Quality of Life Among Patients With High-Grade Glioma Society for Neuro-Oncology Musella Foundation End Brain Cancer Initiative Brain Tumor Network American Brain Tumor Association Glioblastoma Research Organization Brain Tumor Funders' Collaborative Optune Gio® website Nurse.org article: Mysterious Brain Tumor Cluster Grows: Another Nurse Diagnosed at Newton-Wellesley Lori Cappello's contact information: lori.cappello@hmhn.org To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “A glioblastoma actually is the most predominant brain tumor that we do see. It is the most diagnosed of the brain tumors. And then I would say that an anaplastic astrocytoma is probably the second diagnosed. Historically a GBM, they used to say was probably an elderly patient for these. But we are definitely seeing it diagnosed at a much younger age now, definitely much more prevalent for people under 60.” TS 3:17 “Nine times out of ten, either a patient out of nowhere has a seizure, or they present with what they think are stroke-like symptoms. They noticed that they were slurring, or they were becoming more forgetful, or a family member noticed it and said, ‘Hey, what is going on with you?' But usually they present to the [emergency department], and a [computed tomography] scan is always done first. And lo and behold, something is seen.” TS 4:50 “The only other U.S. Food and Drug Administration-approved treatment that has come along in the last 20 years is a device called Optune Gio, which is an alternating electric field that stops cell division at the mitosis stage.” TS 7:45 “They lose so much of their independence, especially if they don't have a caregiver or help. That is huge. Medication management at home, to making sure that they're taking the medication properly, that they are actually taking their medication. Transportation is another huge problem. Getting to and from appointments is a challenge. Those are big issues—real, day-to-day, simple issues that people don't think about.” TS 17:11 “I think that having a brain tumor is very unique in the fact that you really need a dedicated neuro-oncologist. And depending on where you live, there are not a lot in the area. I actually had a patient that was moving out west, and the closest dedicated neuro-oncologist was four hours from them. … if you're not seeing dedicated neuro oncologists, you might not be getting the best treatment for yourself. So I think that having the resources and helping patients find the best care or the best brain tumor society—and there's a bunch of really good brain tumor groups to help patients find the best resources out there. I think that's really, really important for patients to know or for families to know.” TS 19:17 “So trying to help patients, there are always going to be challenges, and there are always going to be ups and downs. But finding that one person that they can go to, that they trust, that they have a great relationship with, whether at the doctor's office or whatever, and being available to them makes such a difference in their journey. I think that that is the most important for anybody in the journey.” TS 22:08 “With brain, there are going to be expectations. They are going to lose functionality at some point—and preparing them for that thing or preparing them for things that can help themselves. Like sometimes I say, ‘Go to the dollar store, get coloring books,' if they have weakness in one hand. Little tricks of the trade that can help them. About treatment options, going through the side effects, preparing them for whatever they can be prepared for.” TS 22:39 “It is not one of the better cancers to have, but it doesn't immediately mean it's a death sentence, and we shouldn't treat them like they're dying. We shouldn't take away their ability to live just because they were diagnosed with it. We shouldn't take away hope.” TS 25:35 “I think there's not enough discussed about [brain malignancies] and the lack of resources for this. These patients need a lot more resources and are available. There's just not enough available for it.” TS 26:59

Overview of the prophecy of Jonah, the most well-known of the minor prophets in the Old Testament. #MinorProphets #ProphecyofJonah #sermon #preaching #ReluctantProphet #Nineveh #Assyria #Tarshish #providence #disobedience #storm #confession #Jonah1 Brief series on the miraculous gifts of the Spirit today in answer to a listener's question. #miraculousgiftsoftheSpirit #Signsandwonders #apostles #authentication #newrevelation #giftofhealing #giftoftongues #Pentecost #snakes #prayer #miracles #Mark16v17-18 #Acts4v29-30 #Acts9v38 #1Corinthians12v29-30 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Welcome to another episode of the Great Business Minds podcast, the definitive show for the business of digital infrastructure. GBM is brought to you by Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry and the telecoms and tech sector work more broadly. Wherever your legal or regulatory needs are (including outer space) Preiskel & Co LLP can support you, so do feel free to reach out to them at www.preiskel.com. This week, Douglas Loewe, CEO of Kao Data, offers insights into the rapidly evolving landscape of data centre real estate and expansion, with a particular focus on the burgeoning artificial intelligence (AI) sector. As Loewe approaches his first anniversary at the helm of Kao Data, he reflects on the key milestones achieved in the company's roadmap. These achievements are set against the backdrop of an industry undergoing significant transformation, driven by the global AI arms race and the increasing demand for data centres engineered specifically for AI applications. The interview delves into Kao Data's strategic positioning within this competitive landscape. Loewe elucidates how the company is adapting its operations and future plans to meet the surge in demand for AI-capable infrastructure while simultaneously addressing critical issues of energy efficiency and sustainability. A significant portion of the discussion centres on the United Kingdom's role in the global AI ecosystem. Loewe offers his perspective on the unique advantages the country presents for data centre operators like Kao Data, highlighting the potential for growth and innovation within this dynamic market. The conversation also touches upon the economic climate and its impact on AI-related investments. Loewe provides insights into how Kao Data's strategy for attracting and allocating capital has evolved over the past year, reflecting the company's agility in responding to market trends and investor expectations. Looking towards the future, Loewe shares his vision for Kao Data over the next three to five years. He outlines what he perceives as the most significant challenges and opportunities facing the company, particularly in relation to the ongoing AI revolution and its implications for the data centre industry. Here at the GBM podcast, we hope you enjoy this episode and do leave us a review and share it with your contacts. We invite you back again for the next episode with another big name in the digital infrastructure space. If you want to get more from the definitive podcast for the business of digital infrastructure, make sure you subscribe to Great Business Minds. See you soon! /////////////////////// This episode features our commercial partner Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry as well as the telecoms and tech sector work more broadly. Visit www.preiskel.com for more information. /////////////////////// Get more from the GBM Podcast on: Official Website LinkedIn Facebook Instagram Twitter YouTube

Overview of the prophecy of Jonah, the most well-known of the minor prophets in the Old Testament. #MinorProphets #ProphecyofJonah #narrative #bigfish #prophesy #Nineveh #Assyria #Providence #fasting #sackcloth #kindnessandcompassion #preachingrepentance #2Kings14v25 #Psalm5 #Psalm18 #Psalm56 #Psalm61 #Psalm65 #Psalm66 #Psalm116 #Jonah A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #pastoral #Humble #Humility #pride #possessions #faith #dignity #James4v10 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Overview of the prophecy of Obadiah, one the minor prophets in the Old Testament. #MinorProphets #ProphecyofObadiah #judgment #Edom #Edomites #pride #intertestamentalperiod #enemiesofGod #ungodly #dayoftheLord #humiliation #proud #Judah #revenge #persecutionoftheChurch Brief series on the miraculous gifts of the Spirit today in answer to a listener's question. #miraculousgiftsoftheSpirit #SufficiencyofScripture #revelationcomplete #lastdays #HolySpirit #spiritualgifts #love #John1v1-3 #Romans12v6-8 #1Corinthians1v5-7 #1Corinthians13 #2Timothy1v13 #2Timothy2v2 #Hebrews1v1-2 #Jude3 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Overview of the prophecy of Amos, one the minor prophets in the Old Testament. #MinorProphets #ProphecyofAmos #sermonsuggestions #FinalJudgment #restoration #NewCovenant #Gentiles #Edom  #spiritualawakening #revival #Amos4v6-13 #Amos911-13 #Acts15v16-17 #Romans8v1 #1Thessalonians1v10 Brief series on the miraculous gifts of the Spirit today in answer to a listener's question. #miraculousgiftsoftheSpirit #miracles #Moses #Elijah #apostles #SonofGod #Messiah #signsandwonders #Exodus4v1-9 #Exodus7v8-12 #Exodus9v16 #1Kings18v36-38 #John20v30-31 #Acts2v43 #2Corinthians12v12 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk  

BUFFALO, NY - April 4, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT." Researchers from Brown University, led by first author Lanlan Zhou and corresponding author Wafik S. El-Deiry, have shown that combining a new class of drugs called imipridones with standard glioblastoma treatments significantly improves outcomes in mice. The study tested ONC201 and its analog ONC206 in combination with radiation therapy and the chemotherapy drug temozolomide (TMZ), a regimen referred to as IRT. This triple therapy slowed tumor growth and extended survival in a mouse model of glioblastoma, offering a potential new strategy for one of the most aggressive and treatment-resistant brain cancers. Glioblastoma is a fast-growing brain tumor with a poor prognosis and limited treatment options. Standard care typically includes surgery, radiation, and TMZ, but most patients still face a short life expectancy. While ONC201 and ONC206 are currently being studied in clinical trials as single agents, there has been limited information on how they interact with standard therapies. This study is the first to show that both drugs work synergistically with radiation and TMZ, strengthening their overall effects. The results showed that in both laboratory-grown tumor cells and mice, the triple therapy significantly slowed cancer cell growth, reduced tumor size, and prolonged survival compared to using any single or double treatment. Mice treated with IRT lived an average of 123 days, with some surviving more than 200 days—far longer than the 44 to 103 days observed with other treatment combinations. In addition to directly killing tumor cells, ONC201 and ONC206 lowered the expression of MGMT, a protein that helps tumors resist chemotherapy, making the treatment more effective. The researchers also found that the triple therapy reshaped the tumor environment. It decreased levels of harmful molecules that promote tumor growth and immune evasion while increasing signals that activate the immune system. This dual action—directly attacking tumors and boosting immune responses—adds to the potential impact of this treatment approach. “Overall, our preclinical findings support further exploration of the ONC201 and ONC206 IRT regimen as a potential treatment for GBM and diffuse gliomas with H3K27M mutations.” While these findings are based on preclinical mouse models, they offer strong support for advancing this triple therapy to clinical trials. ONC201 and ONC206 are promising due to their ability to cross the blood-brain barrier and enhance the effects of standard treatment. This combination could lead to more effective therapies for glioblastoma and other hard-to-treat brain tumors. DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Topics covered : Cancer, Glioblastoma multiforme (GBM), control the controllables, shift in perspective, healthy body and mind, affirmations, positive self talk, appreciation. Alannah Sheehan lives in Tipperary with her husband Martin and their 3 children, Finn (9), Luca (7) and Phoebe (5).And 5 years ago when Phoebe was only a few months old, Alannah was diagnosed with Glioblastoma multiforme, an aggressive type of brain cancer.But today, 5 years on, she's healthy and happy and even though she still has to go for regular scans and deal with the stress and anxiety that goes with that, ultimately, life is good.We spoke 4 years ago but I wanted to chat to her again as she is so inspiring.In this conversation she talks about the power of taking control over what you can control and nourishing your body and mind, every day. Alannah was a chef before her diagnosis and food is her passion. Her go to juice is celery, cucumber and lemon and she drinks it every day.You can subscribe to Alannah's ‘Survive and Thrive' membership to gain access to her delicious recipes, and you can also purchase her gorgeous wellness cards too.Alannah SheehanInstagramALANNAH SHEEHAN (@worth_fighting4) • Instagram photos and videos If you're a fan of what I do, please follow, rate and review in all the usual places.And thanks, as always, for your support of Ready to be Real. Hosted on Acast. See acast.com/privacy for more information.

Radiation therapy or radiotherapy, is a common treatment for cancer, but its effectiveness differs across patients. A recent study published as the cover for Volume 17, Issue 2 of Aging explored why this happens. The findings provide valuable insights, particularly for brain cancers like glioblastoma (GBM) and low-grade gliomas (LGG). Understanding Glioblastoma and Low-Grade Gliomas Glioblastoma and LGG are both brain tumors, but they behave in very different ways. GBM is highly aggressive, with most patients surviving only 12 to 18 months, even with surgery, chemotherapy, and radiation therapy. LGG, on the other hand, grows more slowly, and many patients live for decades with proper care. Despite their differences, LGG and GBM are biologically linked. Some LGG tumors eventually transform into GBM, making early treatment decisions critical. Given radiation therapy's effectiveness in GBM, it has often been assumed that LGG patients would also benefit from it. However, a new study titled “Variability in radiotherapy outcomes across cancer types: a comparative study of glioblastoma multiforme and low-grade gliomas” challenges this assumption. Full blog - https://aging-us.org/2025/03/how-radiation-therapy-affects-tumors-glioblastoma-vs-low-grade-gliomas/ Paper DOI - https://doi.org/10.18632/aging.206212 Corresponding author - Morten Scheibye-Knudsen - mscheibye@sund.ku.dk Video short - https://www.youtube.com/watch?v=j91rzDJHXTE Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206212 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cancer, biomarkers, radiotherapy, GBM, LGG, survival About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY - March 3, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on February 28, 2025, titled “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells." Elham Taheri and Maryam Raeeszadeh-Sarmazdeh from the University of Nevada, Reno, explored a new approach to slowing the spread of glioblastoma multiforme (GBM), the most aggressive and deadly form of brain cancer. Their study highlights the potential of both natural and engineered molecules to block cancer cell movement, offering a promising strategy to combat this challenging disease. Glioblastoma multiforme is difficult to treat because it quickly spreads into healthy brain tissue, making complete surgical removal nearly impossible. A major driver of this invasive behavior is a group of enzymes called matrix metalloproteinases (MMPs), which break down surrounding tissue and create space for cancer cells to spread. Among them, MMP-9 plays a particularly significant role in GBM progression and resistance to current treatments. To address this challenge, the researchers investigated tissue inhibitors of metalloproteinases (TIMPs), natural MMP blockers, and specially engineered versions designed for better effectiveness. The study used cell line models of GBM to test both TIMP-1 and TIMP-3 and their engineered counterparts (mTC1 and mTC3), specific blockers of MMP-9. “Our study focused on minimal TIMP variants, due to their small molecular size and potential in higher cellular uptake and delivery, to assess their potential in cell-based assays.” The results indicated that the engineered TIMPs were just as effective as, or even better than, the natural ones at reducing cancer cell migration and invasion. These findings are particularly promising because previous attempts to block MMPs with small-molecule drugs faced challenges such as poor selectivity and unwanted side effects. In contrast, these engineered TIMPs offer a more targeted and potentially safer approach. One of the greatest obstacles in treating brain cancer is delivering drugs across the blood-brain barrier, a protective layer that prevents many therapeutic compounds from reaching the brain. To address this, the researchers used cell-penetrating peptides to help the TIMP variants reach and enter cancer cells more effectively. Their results confirmed that the engineered TIMPs successfully reached tumor cells, further increasing their potential as a treatment. Additionally, the study found that these engineered TIMPs did not significantly affect healthy cells at lower doses, suggesting they could be used safely. This makes them strong candidates for further drug development. These findings could lead to new treatment options for GBM, a cancer with very few effective therapies. Future research will focus on testing these TIMP variants in animal models to evaluate their long-term effects and safety. Researchers also plan to investigate whether combining these engineered TIMPs with existing treatments, such as chemotherapy or immunotherapy, could improve outcomes. In summary, given the aggressive nature of GBM and the urgent need for better therapies, this study represents an important step forward. If further research confirms these results, engineered TIMPs could become a valuable tool in the fight against brain cancer, offering new hope for improved treatments and patient survival. DOI - https://doi.org/10.18632/oncotarget.28691 Correspondence to - Maryam Raeeszadeh-Sarmazdeh - maryamr@unr.edu Video short - https://www.youtube.com/watch?v=tdBlkOX50D8 To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — March 3, 2025 — A new #research paper was #published in Aging (Aging-US) on February 27, 2025, as the #cover of Volume 17, Issue 2, titled “Variability in radiotherapy outcomes across cancer types: a comparative study of glioblastoma multiforme and low-grade gliomas.” An international research team, led by first author Alexander Veviorskiy from Insilico Medicine AI Limited, Abu Dhabi, UAE, and corresponding author Morten Scheibye-Knudsen from the Center for Healthy Aging, University of Copenhagen, investigated how radiotherapy affects survival in different types of cancer, with a special focus on glioblastoma multiforme (GBM) and low-grade gliomas (LGG). Their findings reveal that radiotherapy has opposite effects in GBM and LGG patients. The study highlights key biological differences between these brain cancer types, emphasizing the need for personalized treatment strategies. Radiotherapy is a standard treatment for many tumors, but its effectiveness varies widely depending on the type of cancer. The researchers began by analyzing data from 32 cancer types using information from The Cancer Genome Atlas (TCGA). They then focused on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), two types of brain cancer with distinct biological behaviors. GBM is an aggressive cancer with poor survival rates, whereas LGG progresses more slowly and often has a better prognosis. “GBM and LGG are particularly interesting to study together because GBM often originates from a preexisting LGG, representing a progression from a lower-grade to a higher-grade malignancy.” The results revealed a striking contrast: patients with GBM who received radiotherapy lived longer, whereas those with LGG had shorter survival times after treatment. To understand the reasons behind this, the researchers analyzed gene expression and signaling pathways. They identify several biological processes that may influence radiotherapy outcomes. For example, GBM tumors have weaker DNA repair mechanisms, making them more vulnerable to radiation-induced damage, which allows radiotherapy to effectively kill cancer cells. In contrast, LGG tumors have stronger DNA repair systems, helping cells survive radiation better and potentially reducing the treatment's effectiveness. Additionally, differences in immune system activity and genetic mutations—such as EGFR alterations—were linked to worse survival in LGG patients who received radiotherapy. These findings highlight the need for a more personalized approach to treating brain cancer. The study proposes that a universal approach to radiotherapy is not appropriate, particularly for patients with LGG. Instead, personalized treatment strategies based on genetic and molecular characteristics could improve patient survival outcomes. The research also raises the possibility of combining radiotherapy with targeted therapies, such as immune-boosting therapies or DNA repair inhibitors, to enhance its effectiveness. In conclusion, this study highlights the complexity of brain cancer treatment and the need for further research to refine therapeutic strategies. By understanding the molecular and genetic differences between the different types of cancers, more effective and personalized approaches can be developed to improve survival and quality of life for brain cancer patients. DOI - https://doi.org/10.18632/aging.206212 Corresponding author - Morten Scheibye-Knudsen - mscheibye@sund.ku.dk Video short - https://www.youtube.com/watch?v=j91rzDJHXTE Visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Welcome to another episode of the Great Business Minds podcast, the definitive show for the business of digital infrastructure. GBM is brought to you by Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry and the telecoms and tech sector work more broadly. Wherever your legal or regulatory needs are (including outer space) Preiskel & Co LLP can support you, so do feel free to reach out to them at www.preiskel.com. On this week's episode, we're doing things slightly differently. For the first time, we have a guest host who takes to the driver's seat for this week's conversation. Our host is Dan Kesler, the co-founder of Digital Garden Tokyo, a new platform fostering collaboration among key stakeholders in digital infrastructure in Japan, focusing on driving transactions and cementing Japan's role as APAC's digital infrastructure leader. Digital Garden Tokyo is hosting its first conference in the Japanese capital on March 17-18, and we look forward to seeing the industry at the Tora-nomon Hills Forum in Central Tokyo. In this conversation, Dan interview William Schrader, who is responsible for paving the way for widespread Internet use by co-founding the first statewide Internet-based network in America. With entrepreneurial zeal, negotiation prowess, and technology know-how, Schrader has been instrumental in growing a global system that connects humans and commerce all over the world. Here at the GBM podcast, we hope you enjoy this episode and do leave us a review and share it with your contacts. We invite you back again for the next episode with another big name in the digital infrastructure space. If you want to get more from the definitive podcast for the business of digital infrastructure, make sure you subscribe to Great Business Minds. See you soon! /////////////////////// This episode features our commercial partner Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry as well as the telecoms and tech sector work more broadly. Visit www.preiskel.com for more information. /////////////////////// Get more from the GBM Podcast on: Official Website LinkedIn Facebook Instagram Twitter YouTube

En este episodio especial, nuestro director Enrique Perret conversa con Miriam Acuña y Andrés Maza de GBM, sobre el contexto actual de la relación México-Estados Unidos. Analizan el impacto de la incertidumbre arancelaria en la economía y cómo los mercados han reaccionado ante las recientes negociaciones. 🔎 ¿Qué efectos tienen estas tensiones en los inversionistas y el comercio bilateral? ¿Cómo pueden las empresas prepararse ante posibles cambios? No te lo pierdas. ¡Escúchalo ahora!

In February 2018, Rebecca Devine, a mum of 4 children, was diagnosed with Glioblastoma (GBM), an aggressive form of brain cancer, and given just 12-15 months to live.Remarkably in 2025 she's still here. And today we're going to talk about her incredible story from diagnosis and treatment, to continual perseverance and ongoing health.I met Rebecca recently at a small gathering hosted by Dr William Li for the angiogenesis foundation, a non profit whose mission is to beat cancer by targeting blood vessels that feed tumours. And it was there that I first came across her story that I'm privileged to share with you today.Today we'll talk about how Rebecca's first experience with cancer was over 20 years ago when her mother was struck with the same diagnosis, and the emotional and physical journey Rebecca went on since 2018. We'll talk about her blend of conventional therapy, diet and lifestyle pursuits as well as the novel vaccine based treatment that she currently uses to keep her condition in remission.Peptide vaccine technology is an emerging immunotherapy strategy aimed at stimulating the immune system to target tumor-specific antigens. GBM, is aggressive and resistant to standard therapies and peptide vaccines hold potential for transforming treatment by leveraging the immune system for tumor-specific targeting.I also firmly believe that the use of novel treatments combined with Rebecca's tenacity, mindset and unwillingness to give up is the reason why she's defied all odds and is currently thriving.

Welcome to another episode of the Great Business Minds podcast, the definitive show for the business of digital infrastructure. GBM is brought to you by Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry and the telecoms and tech sector work more broadly. Wherever your legal or regulatory needs are (including outer space) Preiskel & Co LLP can support you, so do feel free to reach out to them at www.preiskel.com. Recorded live at The Tech Capital's APAC Finance Forum in Jakarta, Indonesia, this episode features the fireside chat with Otto Toto Sugiri, one of Asia's digital infrastructure masterminds of the 21st century.. Pak Toto is DCI's founder and CEO, he is responsible for the overall business and the main point of communication with key stakeholders, including investors, partners, customers and public. Educated in Germany, he is an accomplished IT veteran who began his career in a software company before founding Sigma in 1989. He also founded Indonesia's first Internet Service Provider, Indonet in 1994, and holds an advisory role for Bursa Efek Indonesia. Here at the GBM podcast, we hope you enjoy this episode and do leave us a review and share it with your contacts. We invite you back again for the next episode with another big name in the digital infrastructure space. If you want to get more from the definitive podcast for the business of digital infrastructure, make sure you subscribe to Great Business Minds. See you soon! /////////////////////// This episode features our commercial partner Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry as well as the telecoms and tech sector work more broadly. Visit www.preiskel.com for more information. /////////////////////// Get more from the GBM Podcast on: Official Website LinkedIn Facebook Instagram Twitter YouTube

Tiernan Bradley is currently undefeated as a professional boxer and he has set his sights on major titles in 2025. On the episode, Tiernan talks me through his journey growing up in County Tyrone, winning countless Irish titles as well as claiming European and Commonwealth medals in the amateur ranks. He also discusses his adventures in countries such as Russia, Samoa and the USA . During the journey there have been long periods of inactivity which ultimately left Tiernan having to lose over 30kg's to get to the point where he could restart his career as a professional boxer in late 2020. In the last 4 years he has moved to 10-0 in the pro ranks, moved to Brighton, sparred world class fighters and is currently backed by GBM promotions. We also chat about future plans and his goals going forward.

Welcome to another episode of the Great Business Minds podcast, the definitive show for the business of digital infrastructure. GBM is brought to you by Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry and the telecoms and tech sector work more broadly. Wherever your legal or regulatory needs are (including outer space) Preiskel & Co LLP can support you, so do feel free to reach out to them at www.preiskel.com. Dive into the extraordinary world of hyperscale data centers with our latest episode, recorded live at The Tech Capital's APAC Finance Forum in Jakarta, Indonesia. This episode features the fireside chat with Robin Khuda, the founder and CEO of AirTrunk. This special edition podcast offers an unprecedented look into the journey of a true industry pioneer. Khuda's story is one of remarkable transformation - from an 18-year-old Bangladeshi immigrant in Australia to the architect of a data center empire valued at a staggering A$24 billion. Key highlights of this must-listen episode include: Market Disruption: Discover how Khuda identified a critical gap in the hyperscale data center market and boldly founded AirTrunk to fill it. Resilience in Action: Learn about AirTrunk's brush with bankruptcy and its phoenix-like rise from the ashes, a testament to Khuda's indomitable spirit and strategic acumen. Leadership Insights: Gain invaluable lessons in decision-making and resilience, straight from the experiences of this data center maverick. Industry Milestone: Delve into the details of the recent US$16 billion acquisition by Blackstone and CPP Investments - a record-breaking deal that's reshaping the data center landscape. This episode is not just a story of personal triumph; it's a masterclass in identifying opportunities, navigating challenges, and driving innovation in the fast-paced world of digital infrastructure. Whether you're a tech enthusiast, an aspiring entrepreneur, or a seasoned industry professional, Khuda's insights offer a wealth of knowledge and inspiration. Here at the GBM podcast, we hope you enjoy this episode and do leave us a review and share it with your contacts. We invite you back again for the next episode with another big name in the digital infrastructure space. If you want to get more from the definitive podcast for the business of digital infrastructure, make sure you subscribe to Great Business Minds. See you soon! /////////////////////// This episode features our commercial partner Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry as well as the telecoms and tech sector work more broadly. Visit www.preiskel.com for more information. /////////////////////// Get more from the GBM Podcast on: Official Website LinkedIn Facebook Instagram Twitter YouTube

Send us a textIn this captivating episode of Brain Tumor Talk, we sit down with the legendary Dr. Robert F. Spetzler, whose groundbreaking career has left an indelible mark on the world of medicine. From developing life-saving techniques like cardiac standstill and the Spetzler-Martin grading system to a childhood experience with tetanus that shaped his empathy as a physician, Dr. Spetzler shares the defining moments of his journey.We delve into the critical role of teamwork in achieving medical breakthroughs and the power of subspecialization in improving patient outcomes. Dr. Spetzler reflects on the emotional resilience required in neurosurgery, offering heartfelt anecdotes about the challenges and triumphs faced by surgeons.Join us as we celebrate Dr. Spetzler's extraordinary legacy and explore the bright future of neurosurgery through his unique insights, inspiring stories, and unwavering commitment to improving lives.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

Check out this week's QuadCast as we highlight ideal adjuvant management of endometrial cancer from GOG 258, the best approach to locally recurrent rectal cancer, and also highlight recurrent GBM management guidelines. Welcome to 2025! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

In episode 83 of the Summits Podcast, Vince Todd, Jr. is joined by Nicole Rule, Associate Vice President in Oncology Clinical Trial Acceleration at Eli Lilly and Company. Tune in as Nicole shares the benefits of cancer clinical trials and the cancer story that fuels her fight against the disease. The content and views expressed are my own and do not represent the views of my employer, Eli Lilly and Company.

Send us a textWhat happens when life throws a curveball with a diagnosis that changes everything? Join us for an inspiring episode of Brain Tumor Talk where we welcome Erin and DJ Stewart, the dynamic duo behind Head for the Cure and the Rare Enough podcast. DJ, who faced the daunting diagnosis of glioblastoma at just 28 years old, shares his incredible journey alongside Erin, his loving wife and unwavering caregiver. Together, they reveal the challenges and triumphs of living with this aggressive brain cancer while turning their story into a beacon of hope and advocacy for the brain tumor community.Navigating the roller coaster of medical treatments and the emotional weight of uncertainty, Erin and DJ open up about the pivotal role of communication in their relationship. From exploring treatments to DJ's passion for skateboarding, they discuss how staying proactive and embracing life's joys have been essential. We delve into their advocacy efforts, emphasizing the importance of caregivers and the support systems needed to manage caregiver burnout and ensure emotional resilience.In a heartwarming turn, Erin and DJ reflect on their unexpected journey into parenthood with their baby Ellis. They share how a simple documentary project became a life-changing exploration across the country, connecting them with communities affected by brain cancer. By focusing on optimism, community, and the powerful lessons learned from being part of a loving support network, Erin and DJ highlight the transformative power of love, family, and the joy of living fully even in the face of daunting odds.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

Welcome to Eps. 257! Playing the sounds of New House and Tech House for 60 mins. Listen live with our newest CHNR Syndication Network Partner. 10PM Central Time, 8PM Thursday Houswerx from Austin, Tx. Listen to this mixshow with any of our online radio partners Club Sabroso Radio Network in Punta Cana, Dominican Republic.  Follow us on social Media: Instagram: https://www.instagram.com/daknocturne/ X: https://twitter.com/CHNRSocal Tracklist: #    Artwork    Track Title    Artist    Album    Genre    BPM    Rating    Time    Key    Date Added 1        I Only Smoke When I Drink (Claptone Remix) (Extended Mix)    Claptone, nimino    I Only Smoke When I Drink (Claptone Remix)    House    126.00             05:22    Bm    2024-12-03 2        We Get Down (Extended Mix)    Todd Terry, Jason Herd    We Get Down (Extended Mix)    House    127.00             06:52    Dm    2024-12-03 3        All I Want (Extended Mix)    Alexander Som    All I Want (Extended Mix)    House    128.00             04:19    Bbm    2024-12-03 4        Take Me There (Extended Mix)    Solardo, Hayley May    Take Me There (Extended Mix)    House    130.00             05:28    Dbm    2024-12-03 5        Find The Way (Smokey Bubblin' B Remix - Edit)    Peggy Gou    Find The Way (Smokey Bubblin' B Remix)    House    131.00             03:19    Gm    2024-12-03 6        This Groove (Extended Mix)    Airwolf Paradise    This Groove    House    130.00             05:13    Fm    2024-12-03 7        Piano Banger (Original Mix)    Big Miz, Bessa (Sco)    Piano Banger    House    130.00             04:03    Gbm    2024-12-03 8        Maradona (Extended)    Watzgood    Maradona    House    130.00             04:17    Dm    2024-12-03 9        Dance 2 Haus (Original Mix)    Danny Snowden    Dance 2 Haus    Tech House    131.00             06:11    Cm    2024-12-03 10        Don't Call Me Baby (Original Mix)    Cyava    Don't Call Me Baby    Tech House    130.00             05:40    Ab    2024-12-03 11        One Man With A Gun (Original Mix)    Sergio Borja, Nahum Nieves, Ralph (VE)    Reggealize EP    Tech House    130.00             05:47    Cm    2024-12-03 12        Latin Thing (Original Mix)    96 Vibe, Nautik (US)    Latin Thing    Tech House    130.00             05:24    Bm    2024-12-03 13        Atemporal (Original Mix)    Sunday Noise, Cris Ocana    Kilos x Saco EP    Tech House    129.00             05:49    Bbm    2024-12-03 14        Rise Up (Extended Mix)    Yuuki Yoshiyama    Rise Up    Tech House    128.00             06:02    Ebm    2024-12-03 15        LE' BLANCK (Original Mix)    Kenneth Palma    MIAMI 2024    Tech House    127.00             06:23    Ab    2024-12-03 16        Won't Look Back (Original Mix)    Duke Dumont    Won't Look Back    House    124.00             04:30    G#m    2024-12-03

Welcome to Eps. 256! Playing the sounds of New House and Tech House for 60 mins. Listen live with our newest CHNR Syndication Network Partner. 10PM Central Time, 8PM Thursday Houswerx from Austin, Tx. Listen to this mixshow with any of our online radio partners Club Sabroso Radio Network in Punta Cana, Dominican Republic.  Follow us on social Media: Instagram: https://www.instagram.com/daknocturne/ X: https://twitter.com/CHNRSocal Tracklist: #    Artwork    Track Title    Artist    Album    Genre    BPM    Rating    Time    Key    Date Added 1        Gold Chain Alimony (Arturo Garces Sugar Daddy Remix)    Jaemus    Gold Chain Alimony    Jackin House    125.00             06:20    Abm    2024-11-26 2        In The Disco (Original Mix)    Phil Weeks    That House Groove    Jackin House    125.00             06:45    Gbm    2024-11-26 3        Body Dub (Original Mix)    FLETCH (GB)    Moxy Muzik ADE VA, Part. 1    Jackin House    126.00             05:52    Em    2024-11-26 4        Anybody Trippin (Extended Mix)    NickySnax    Anybody Trippin' (Extended Mix)    Jackin House    127.00             04:49    Gbm    2024-11-26 5        Feel It (James Curd Remix)    Saison    Feel It (James Curd Remix)    Jackin House    128.00             07:08    Am    2024-11-26 6        Street Love (Original Mix)    Bora Uzer    Street Love / Magic Kind    House    128.00             06:01    Am    2024-11-26 7        I Need You (Original Mix)    Us Two    Breaking Dollars EP    House    128.00             06:30    Abm    2024-11-26 8        Ça Va Sans Dire (Original Mix)    Sem Jacobs    Une Nuit À La Cour    House    127.00             07:07    Bbm    2024-11-26 9        Gotta Feel Good (Original)    Hatiras    Gotta Feel Good    House    127.00             05:33    Bb    2024-11-26 10        House Music Saved Me (Extended Mix)    Trimtone, Mixed Methods    House Music Saved Me    House    126.00             06:03    Bm    2024-11-26 11        Keep Moving (Original Mix)    Cesar Zu    keep Moving    Tech House    125.00             06:08    Cm    2024-11-26 12        Riding (Extended Mix)    DJ Entwan, Albert Lopez    Black Seven | ADE Sampler    Tech House    125.00             05:46    Cm    2024-11-26 13        Sunrise Ft Krysten Cummings (James Hurr Remix)    Hoxton Whores    Sunrise Ft Krysten Cummings    Tech House    126.00             06:13    Cm    2024-11-26 14        Formanto (Original Mix)    Max Chapman    Formanto    Tech House    126.00             06:38    A#m    2024-11-26 15        Ride On Time (Original Mix)    BLACK BOX    Dreamland    House    118.72             04:32    Am    2024-11-26

Merry Christmas from Christian and Jonathan of Grace Bond Ministries! On this month's episode, GBM takes a deep dive into the birth of Jesus, which will be celebrated across the world on December 25! After opening up with a reading of the account of His birth in Luke 2, we discuss a few aspects. The first is the different messianic prophecies of Jesus found in the Old Testament. We want you to think like these 1st century Jews who had been expecting the Messiah for a long time. What were they expected? And, did Mary know? ;) Second, we pick out a couple of key points found in the birth accounts. This, we believe, will encourage all of us to slow down and dive into the important details of the accounts of Jesus's birth! Thirdly, we discuss why the birth of Jesus means so much, even 2000 years after the Messiah was born! This was a great podcast, and will most definitely get us set for Christmas day, when we all celebrate the birth of our savior and messiah! Thanks for tuning in! Please be sure to like, share, and subscribe to help grow the ministry! Want to know more about us or watch/listen on a different platform? Check out our website: gracebondministries.weebly.com! You can also email us at gracebondministries@gmail.com!

Comedians Ari Shaffir & Adrienne Iapalucci join Big Jay Oakerson, Luis J. Gomez, & Dave Smith to discuss Luis' recent incident with an airplane phone talker, GBM's take on the Mike Tyson vs Jake Paul fight, and Dave's awkward situation regarding the purchase of a portrait of himself. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 11/19/24Support our sponsors!Go to YoKratom.com - home of the $60 kilo!Fans over the age of 21, head to YoDelta.com and use promo code GAS for 25% off your order!Visit Autoblow.com and use promo code SKANKS for 10% off your first order!Download the PrizePicks app today and use code SKANKS for a first deposit match up to $100!Control Body Odor ANYWHERE with @shop.mando and get $5 off your Starter Pack (that's over 40% off) with promo code LEGION at ShopMando.com---------------

In this episode of Brain Tumor Talk, we dive into the world of biomarker testing—a powerful tool in brain tumor diagnosis and treatment. With the 2021 World Health Organization (WHO) classification emphasizing the role of molecular biomarkers, understanding tumor profiling is more crucial than ever. Shwetal Mehta, PhD, and Charuta Furey, MD, join us on the episode to break down the science in an accessible way that empowers patients.Tune in to learn the essentials, so you're ready to discuss biomarker testing with your care team.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

Chris Schuler opens up about his experience as a caregiver, navigating the challenges of neurodegeneration, particularly his father's glioblastoma diagnosis. He shares the emotional turmoil, confusion, along with the overwhelming process of navigating the healthcare system. The conversation underscores the importance of raising awareness and understanding of neurodegenerative diseases and their impact on families. We also delve into the problematic nature of the 'standard of care' in oncology, highlighting the critical need to advocate for yourself. Check out the article Samira referenced towards the end of this episode here. My Cancer GPS™ is coming! Step-by-step subway maps that guide you through the entire cancer experience. Learn more here!⁠ Key Highlights: 1. Self-advocacy is critical in getting the care that's best for you, so ask questions, and get involved. Your healthcare team cares for you and wants to see you back on your feet, but no one can care more than you do. 2. Caregivers need to look after themselves, too. It can feel like there's no room for yourself, but you must find joy. Find joy so that you can cherish whoever is under your care. 3. The role of a caregiver is both rewarding and demanding. Being an advocate for a loved one is a necessary responsibility because the standard is not always the best care you can receive for your individual case. About our guest: Chris Schuler is a staunch brain cancer awareness advocate. He was the primary caregiver to his late Dad, Donald Schuler, who was diagnosed with GBM in July 2021. He works closely with organizations across the globe, amplifying their critical work and building key relationships to further improve outcomes for patients. He recently finished a year-long consultancy with Cure Brain Cancer Foundation, an Australian non-profit dedicated to improving outcomes in brain cancer. He's currently a Venture Partner with Varia Ventures, working to raise awareness for emerging venture funds dedicated to uncovering and funding innovative discoveries to improve brain health. He also works closely with SageMedic, a precision oncology start-up supporting patients looking for the most effective treatment for cancer. Chris continues on as his Dad's caregiver — caregiver to his life, legacy and memory.     At 33 minutes and 18 seconds: “From that very moment, I went from being a lot of things in my life, being a son, a nephew, a grandson, a friend, eventually an uncle, a husband, a father. Now I am a caregiver. I want to say nothing prepared me for that. Everything prepared me for that. The way I was raised, everything I experienced in my life, every up, every down, every victory, every rejection, everything led to this moment where I am now my dad's caregiver with my mom. I call myself the primary caregiver because there was something she couldn't do for him, and how do you become an advocate? How do you take on what seems insurmountable? And I say to any listeners, you can do it. You have what's in you to do it, to be the very best caregiver, because all you need is one prerequisite to be a caregiver. You need to be able to love. If you can love, you are a caregiver.” Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Javier Morodo es un inversionista y experto financiero. Ha trabajado en empresas como GBM y Bitso y es socio fundador de fondos de inversión, ángel inversionista y miembro del consejo de varias startups.  Ha sido nombrado como referente por múltiples publicaciones como los 30 de 30 de la revista expansión y es columnista de Forbes. Javier busca ayudar a que las personas alcancen la libertad y puedan crear un patrimonio propio a través de programas, conferencias y contenidos educativos. En este episodio hablamos de temas como el juego del dinero y cómo cambiar tu relación con él, saber cuáles son las cosas que de verdad importan y cómo evitar que se nos pasen desapercibidas.

Comedians Derek Gaines & Brendan Sagalow join Big Jay Oakerson, Luis J. Gomez, and Dave Smith to discuss how GBM ended up with a black eye after a night of drinking, the Australian woman facing charges for filming an explicit video with a trout, and Luis and Jay's upcoming rap battle at Skankfest. Plus, the gang reviews entries into the "Worst Life" contest for Skankfest 2024 Golden Tickets. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Air Date: 08/27/24Support our sponsors!Go to YoKratom.com, home of the $60 kilo!Fans over the age of 21, head to YoDelta.com and use promo code GAS for 25% off your order!Head to SmallBatchCigar.com and use promo code LOS10 for 10% off your order plus 5% rewards points! Download the PrizePicks app today and use code SKANKS for a first deposit match up to $100! GET YOUR SKANKFEST VEGAS 2024 TICKETS HERE: SKANKFEST.COM